BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.

A Nourry, A Zambon, L Davies, I Niculescu-Duvaz, HP Dijkstra, D Ménard, C Gaulon, D Niculescu-Duvaz, BM Suijkerbuijk, F Friedlos, HA Manne, R Kirk, S. Whittaker, R. Marais, CJ Springer

Research output: Contribution to journalArticlepeer-review

Abstract

We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A−B−C system characterized by a para-substituted central aromatic core connected to an imidazo[4,5]pyridin-2-one scaffold and a substituted urea linker. Here, we present a new series of BRAF inhibitors in which the central phenyl ring connects to the hinge binder and substrate pocket of BRAF with a meta-substitution pattern. The optimization of this new scaffold led to the development of low-nanomolar inhibitors that permits the use of a wider range of linkers and terminal C rings while enhancing the selectivity for the BRAF enzyme in comparison to the para series.
Original languageEnglish
Pages (from-to)1964-1978
Number of pages15
JournalJournal of Medicinal Chemistry
Volume53
Issue number5
DOIs
Publication statusPublished - 11 Feb 2010

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.'. Together they form a unique fingerprint.

Cite this